GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Margin of Safety % (DCF Dividends Based)

Arena Pharmaceuticals (FRA:RN3N) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Arena Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.


Competitive Comparison of Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based) falls into.



Arena Pharmaceuticals Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry
Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines